CAJ | 학술논문

目的：探讨吉西他滨联合奈达铂在晚期肺鳞癌中的临床应用效果。方法选取2011年8月至2012年11月我院收治的68例晚期肺鳞癌患者，随机分为吉西他滨联合奈达铂组(观察组)和吉西他滨联合顺铂组(对照组)，每组各34例，比较两组患者治疗疗效、毒副反应、生存率和中位生存期。结果两组患者均顺利完成治疗，观察组有效率(44.1%)虽然高于对照组(35.2%)，但差异无统计学意义(P>0.05)；两组的毒副反应主要表现为骨髓抑制，其次是胃肠道反应，且观察组Ⅰ级和Ⅱ级不良反应的发生率明显低于对照组(P<0.05)。Ⅲ级和Ⅳ级不良反应也低于对照组(P<0.05)，两组均未发现有严重肝功能损害和周围神经的毒性损害。结论西他滨联合奈达铂治疗晚期肺鳞癌疗效肯定，且毒副反应轻，耐受性好，值得临床推广。
목적：탐토길서타빈연합내체박재만기폐린암중적림상응용효과。방법선취2011년8월지2012년11월아원수치적68례만기폐린암환자，수궤분위길서타빈연합내체박조(관찰조)화길서타빈연합순박조(대조조)，매조각34례，비교량조환자치료료효、독부반응、생존솔화중위생존기。결과량조환자균순리완성치료，관찰조유효솔(44.1%)수연고우대조조(35.2%)，단차이무통계학의의(P>0.05)；량조적독부반응주요표현위골수억제，기차시위장도반응，차관찰조Ⅰ급화Ⅱ급불량반응적발생솔명현저우대조조(P<0.05)。Ⅲ급화Ⅳ급불량반응야저우대조조(P<0.05)，량조균미발현유엄중간공능손해화주위신경적독성손해。결론서타빈연합내체박치료만기폐린암료효긍정，차독부반응경，내수성호，치득림상추엄。
Objective To explore the clinic application effect of gemcitabine combined with nedaplatin in advanced squamous cell lung cancer. Methods From August 2011 to November 2012, 68 patients with advanced squamous cell lung cancer from our hospital were enrolled in this study, which were randomly divided into gemcitabi-ne combined with nedaplatin group (observation goup) and gemcitabine plus cisplatin group (control group). There were 34 cases in each group. Treatment efficacy, side-effect, survival rate and the median survival period were com-pared between the two groups. Results Patients from the two groups all successfully completed treatment. The effec-tive rate of observation group was higher than of control group (44.1%versus 35.2%), but the difference was not statis-tically significant (P>0.05). The main toxicity of two groups was bone marrow suppression, followed by gastrointesti-nal reaction. In observation group, the incidence of grade I and gradeⅡadverse reaction was significantly lower than in control group (P<0.05). The incidence of gradeⅢand gradeⅣadverse reaction in observation group was also be-low that in control group (P<0.05). There was no severe injury in liver function and peripheral nerve toxic damage in two groups. Conclusion Curative effect of gemcitabine combined with nedaplatin in the treatment of advanced lung carcinoma is positive with light toxicity reaction and good tolerability, so it is worthy of clinical promotion.